A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Janssen Research & Development, LLC
J-Pharma Co., Ltd.
Centre Leon Berard
Peking University
Bristol-Myers Squibb
Hoffmann-La Roche
Bristol-Myers Squibb
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
AstraZeneca
Medical College of Wisconsin
Incyte Corporation
University of California, Irvine
Sun Yat-sen University
Northwell Health
University of Campania Luigi Vanvitelli
GlaxoSmithKline
Shanghai Zhongshan Hospital
Incyte Corporation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
UNICANCER
UNICANCER
Massachusetts General Hospital
Chang Gung Memorial Hospital
Sun Yat-sen University
GERCOR - Multidisciplinary Oncology Cooperative Group
Weill Medical College of Cornell University
Providence Health & Services
Nanjing Tianyinshan Hospital
McGill University Health Centre/Research Institute of the McGill University Health Centre
St. Olavs Hospital
Centre Hospitalier Universitaire Dijon
Azienda Ospedaliera Universitaria Integrata Verona
Alethia Biotherapeutics
The Methodist Hospital Research Institute
University Hospital Tuebingen
Merus B.V.
UNICANCER
Centre Hospitalier Universitaire de Besancon
Seoul National University Hospital
Fudan University
UNICANCER
Gustave Roussy, Cancer Campus, Grand Paris
Fudan University
Sixth Affiliated Hospital, Sun Yat-sen University
Sixth Affiliated Hospital, Sun Yat-sen University
Sun Yat-sen University
Sun Yat-sen University
Catharina Ziekenhuis Eindhoven